Time filter

Source Type

McDonald P.C.,Cancer Research Center and Cancer Agency | Winum J.-Y.,National Graduate School of Chemistry, Montpellier | Supuran C.T.,University of Florence | Dedhar S.,Cancer Research Center and Cancer Agency | Dedhar S.,University of British Columbia
Oncotarget | Year: 2012

Carbonic anhydrase IX (CAIX) is a hypoxia-inducible enzyme that is overexpressed by cancer cells from many tumor types, and is a component of the pH regulatory system invoked by these cells to combat the deleterious effects of a high rate of glycolytic metabolism. CAIX functions to help produce and maintain an intracellular pH (pHi) favorable for tumor cell growth and survival, while at the same time participating in the generation of an increasingly acidic extracellular space, facilitating tumor cell invasiveness. Pharmacologic interference of CAIX catalytic activity using monoclonal antibodies or CAIX-specific small molecule inhibitors, consequently disrupting pH regulation by cancer cells, has been shown recently to impair primary tumor growth and metastasis. Many of these agents are in preclinical or clinical development and constitute a novel, targeted strategy for cancer therapy. © McDonald et al. Source

Pacchiano F.,University of Florence | Carta F.,University of Florence | McDonald P.C.,Cancer Research Center and Cancer Agency | Lou Y.,Cancer Research Center and Cancer Agency | And 5 more authors.
Journal of Medicinal Chemistry | Year: 2011

A series of ureido-substituted benzenesulfonamides was prepared that showed a very interesting profile for the inhibition of several human carbonic anhydrases (hCAs, EC, such as hCAs I and II (cytosolic isoforms) and hCAs IX and XII (transmembrane, tumor-associated enzymes). Excellent inhibition of all these isoforms has been observed with various members of the series, depending on the substitution pattern of the urea moiety. Several low nanomolar CA IX/XII inhibitors also showing good selectivity for the transmembrane over the cytosolic isoforms have been discovered. One of them, 4-{[(3′- nirophenyl)carbamoyl]amino}benzenesulfonamide, significantly inhibited the formation of metastases by the highly aggressive 4T1 mammary tumor cells at pharmacologic concentrations of 45 mg/kg, constituting an interesting candidate for the development of conceptually novel antimetastatic drugs. © 2011 American Chemical Society. Source

Discover hidden collaborations